{'fraction_non_alphanumeric': 0.02333065164923572, 'fraction_numerical': 0.003218020917135961, 'mean_word_length': 5.760869565217392, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Antisense agents against antibiotic-resistant bacteria.

The dramatically increasing levels of antibiotic resistance are being seen worldwide, and is a significant threat to public health. Antibiotic and drug resistance is seen in various bacterial species. Antibiotic resistance is associated with increased morbidity and mortality and increased treatment costs. Antisense-relevant technologies include the utilization of oligonucleotide molecules to interfere with gene expression, as a new technique for the treatment of antibiotic-resistant bacteria has been proposed antisense agents or nucleic acids analogs with antibacterial properties, which are commonly very short and their size almost 10-20 bases and can be hinted to peptide nucleic acids (PNAs), phosphorodiamidate morpholino oligomers (PPMOs) and locked nucleic acids (LNAs). This review highlights that PNAs, PPMOs, and LNAs target the genes that cause destroy the gene and inhibit the growth of bacteria. These results open a new perspective for therapeutic intervention. In future studies, it is necessary to examine different aspects of antisense agents, for example, safety, toxicity, and pharmacokinetic properties of antisense agents to be employed in clinical treatment.